BioCentury | Feb 26, 2020
Product Development

COVID-19: A growing list of new vaccines and therapies in development

As the response to the ongoing COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis. Repurposed agents being tested for...
BioCentury | Feb 26, 2020
Product Development

COVID-19: A growing list of new vaccines and therapies in development

As the response to the ongoing COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis. Repurposed agents being tested for...
BC Extra | Jan 31, 2020
Clinical News

A dozen vaccine programs under way as WHO declares coronavirus public health emergency

WHO declared the coronavirus outbreak a Public Health Emergency of International Concern Thursday and called for China and countries around the world to take public health steps to contain the virus. WHO also stressed the...
BC Extra | Jan 27, 2020
Company News

J&J developing coronavirus vaccine, at least nine other vaccines under development

Two more companies have announced that they are developing vaccines to protect against the 2019-nCoV outbreak that was first detected in Wuhan, China, bringing the total number of vaccine development programs to at least 10....
BC Week In Review | Nov 30, 2018
Company News

Leidos, GeoVax to develop immonotherapeutic vaccines

GeoVax Labs Inc. (OTCBB:GOVX) and Leidos Holdings Inc. (NYSE:LDOS) partnered to develop immunotherapeutic vaccines using GeoVax’s Modified Vaccinia Ankara-Virus Like Particles (MVA-VLP) platform and undisclosed PD-1 inhibitors from Leidos. GeoVax will design and characterize the...
BC Week In Review | Aug 31, 2018
Company News

GeoVax, PharmaJet partner to study needle-free delivery of Zika vaccine

GeoVax Labs Inc. (OTCQB:GOVX) partnered with PharmaJet Inc. (Golden, Colo.) to evaluate PharmaJet’s needle-free injection system to deliver GeoVax’s preclinical Zika vaccine GEO-ZM02. The studies will be conducted at the Division of Vector-Borne Diseases, U.S....
BC Week In Review | Mar 16, 2018
Clinical News

GeoVax reports non-human primate data for Ebola vaccine

GeoVax Labs Inc. (OTCQB:GOVX) reported preclinical data from rhesus macaques challenged with a lethal dose of Ebola virus showing that a single intramuscular dose of GEO-EM01 conferred 100% protection against Ebola virus infection at four...
BC Innovations | Sep 27, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Viral hemorrhagic fever Non-human primates studies suggest mAbs against Lassa virus glycoprotein could help prevent or treat Lassa fever. In a cynomolgus macaque lethal Lassa virus challenge model, each of five human mAbs against...
BC Extra | Sep 6, 2017
Preclinical News

Human mAbs could treat Lassa fever

In a paper published in Nature Medicine , researchers at the University of Texas , Tulane University and Zalgen Labs LLC (Germantown, Md.) showed that Lassa virus glycoprotein-neutralizing mAbs rescued non-human primates infected with Lassa virus, suggesting...
BC Week In Review | Feb 10, 2017
Clinical News

GOVX-B11: Ph I HVTN 114 started

GeoVax said the HIV Vaccine Trials Network (HVTN) began the double-blind, placebo-controlled, U.S. Phase I HVTN 114 trial to evaluate the company's intramuscular GOVX-B11 with or without AIDSVAX B/E vaccine vs. AIDSVAX B/E alone at...
Items per page:
1 - 10 of 69
BioCentury | Feb 26, 2020
Product Development

COVID-19: A growing list of new vaccines and therapies in development

As the response to the ongoing COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis. Repurposed agents being tested for...
BioCentury | Feb 26, 2020
Product Development

COVID-19: A growing list of new vaccines and therapies in development

As the response to the ongoing COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis. Repurposed agents being tested for...
BC Extra | Jan 31, 2020
Clinical News

A dozen vaccine programs under way as WHO declares coronavirus public health emergency

WHO declared the coronavirus outbreak a Public Health Emergency of International Concern Thursday and called for China and countries around the world to take public health steps to contain the virus. WHO also stressed the...
BC Extra | Jan 27, 2020
Company News

J&J developing coronavirus vaccine, at least nine other vaccines under development

Two more companies have announced that they are developing vaccines to protect against the 2019-nCoV outbreak that was first detected in Wuhan, China, bringing the total number of vaccine development programs to at least 10....
BC Week In Review | Nov 30, 2018
Company News

Leidos, GeoVax to develop immonotherapeutic vaccines

GeoVax Labs Inc. (OTCBB:GOVX) and Leidos Holdings Inc. (NYSE:LDOS) partnered to develop immunotherapeutic vaccines using GeoVax’s Modified Vaccinia Ankara-Virus Like Particles (MVA-VLP) platform and undisclosed PD-1 inhibitors from Leidos. GeoVax will design and characterize the...
BC Week In Review | Aug 31, 2018
Company News

GeoVax, PharmaJet partner to study needle-free delivery of Zika vaccine

GeoVax Labs Inc. (OTCQB:GOVX) partnered with PharmaJet Inc. (Golden, Colo.) to evaluate PharmaJet’s needle-free injection system to deliver GeoVax’s preclinical Zika vaccine GEO-ZM02. The studies will be conducted at the Division of Vector-Borne Diseases, U.S....
BC Week In Review | Mar 16, 2018
Clinical News

GeoVax reports non-human primate data for Ebola vaccine

GeoVax Labs Inc. (OTCQB:GOVX) reported preclinical data from rhesus macaques challenged with a lethal dose of Ebola virus showing that a single intramuscular dose of GEO-EM01 conferred 100% protection against Ebola virus infection at four...
BC Innovations | Sep 27, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Viral hemorrhagic fever Non-human primates studies suggest mAbs against Lassa virus glycoprotein could help prevent or treat Lassa fever. In a cynomolgus macaque lethal Lassa virus challenge model, each of five human mAbs against...
BC Extra | Sep 6, 2017
Preclinical News

Human mAbs could treat Lassa fever

In a paper published in Nature Medicine , researchers at the University of Texas , Tulane University and Zalgen Labs LLC (Germantown, Md.) showed that Lassa virus glycoprotein-neutralizing mAbs rescued non-human primates infected with Lassa virus, suggesting...
BC Week In Review | Feb 10, 2017
Clinical News

GOVX-B11: Ph I HVTN 114 started

GeoVax said the HIV Vaccine Trials Network (HVTN) began the double-blind, placebo-controlled, U.S. Phase I HVTN 114 trial to evaluate the company's intramuscular GOVX-B11 with or without AIDSVAX B/E vaccine vs. AIDSVAX B/E alone at...
Items per page:
1 - 10 of 69